DAFNA Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

DAFNA Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.16M	Buy	377,059 +36,200	+11%	+$257K	0.49%	45
2025 Q4	$3.38M	Sell	340,859 -17,224	-5%	-$157K	0.79%	34
2025 Q3	$2.38M	Sell	358,083 -20,000	-5%	-$96.7K	0.59%	39
2025 Q2	$1.52M	Hold	378,083	–	–	0.42%	45
2025 Q1	$1.31M	Sell	378,083 -15,000	-4%	-$66.5K	0.37%	48
2024 Q4	$2.59M	Buy	393,083 +142,500	+57%	+$1.12M	0.66%	35
2024 Q3	$2.27M	Buy	+250,583	New	+$2.99M	0.54%	43

Other funds holding LXEO

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DAFNA Capital Management's LXEO Position: Q1 2026 in Review

DAFNA Capital Management increased its Lexeo Therapeutics (LXEO) stake by 11% in Q1 2026, buying an estimated $257K and bringing the position to 377,059 shares worth $2.16M. The position accounts for 0.49% of the portfolio, ranked #45.

DAFNA Capital Management first reported a position in LXEO in Q3 2024 and has held it in 7 quarters since. The position peaked at $3.38M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

DAFNA Capital Management held 377,059 shares of Lexeo Therapeutics worth $2.16M as of Q1 2026.
DAFNA Capital Management bought 36,200 Lexeo Therapeutics shares in Q1 2026, an estimated $257K.
Lexeo Therapeutics made up 0.49% of DAFNA Capital Management's portfolio in Q1 2026, its #45 holding.
DAFNA Capital Management first reported a position in Lexeo Therapeutics in Q3 2024 and has held it in 7 quarters since.
DAFNA Capital Management's Lexeo Therapeutics position peaked at $3.38M in Q4 2025.
139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.